Projects per year
Personal profile
Personal profile
During her postdoctoral training, Dr. Zhao conducted research on amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease. She investigated the roles of glutamate-mediated cytotoxicity, immune-mediated injury, and oxidative stress in motor neuron death. She also investigated the potential for a new phospholipid agent, VP025, to inhibit immune activation and protect motor neurons from injury. After completing her postdoctoral fellowship, Dr. Zhao joined the Methodist Hospital Research Institute as a scientist in the Department of Neurology.
Research interests
Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a progressive neurodegenerative disease that attacks motor neurons in the brain and spinal cord. Dr. Zhao is interested in the underlying mechanisms of neuroinflammation on motor neuron death and relevant therapeutic targets. Current research efforts aim to understand the roles of microglia/monocytes and T-cells on immune-mediated injury and repair in ALS. Dr. Zhao is investigating the neuroprotective potential of regulatory immune cells as new therapeutic options for ALS. Gene mutations on SOD1, TDP-43, and C9ORF72 have been linked to ALS. Dr. Zhao is also interested in the pathology of various mutant proteins as well as abnormal peptides, and how they affect interactions among motor neurons, microglia, and T-cells in ALS.
Education/Academic qualification
Neurology, Postdoctoral Fellowship, Baylor College of Medicine
Neurology, MD, Beijing Medical University, Beijing
Neurology, PhD, Peking University
Free-text keywords
- ALS
- Lou Gehrig’s disease
- Immune Suppression
- Inflammation
- Neuroprotection
- Neurocytotoxicity
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
A Study of Biological Markers for the Nervous and Immune Systems and Free Radical Mediated Processes in Amyotrophic Lateral Sclerosis (ALS)
Appel, S. H. (PI), Beers, D. (Key Personnel), Greene, E. P. (Key Personnel), Lai, E. C. (Key Personnel), Liao, B. (Key Personnel), Shroff, S. (Key Personnel) & Zhao, W. (Key Personnel)
8/13/20 → …
Project: Clinical Trial
-
Inflamatory and IPSC Markers and Models of ALS
Appel, S. H. (PI) & Zhao, W. (Key Personnel)
2/1/18 → 2/1/19
Project: Non Profit
-
Immune Mechanisms in Amyotrophic Lateral Sclerosis
Appel, S. H. (PI), Beers, D. (Project Director) & Zhao, W. (Project Director)
Muscular Dystrophy Association
5/1/14 → 4/30/17
Project: Non Profit
-
Blocking TLR-Activation of Regulatory T cells Slows Disease in ALS
Appel, S. H. (PI), Beers, D. (CoI) & Zhao, W. (CoI)
Natl Inst of Neuro Disorders and Stroke
3/15/13 → 8/31/15
Project: Federal Funding Agencies
-
CD4+CD25+ Treg cell regulate microglia and provide neuroprotection in ALS
Zhao, W. (PI)
Natl Inst of Neuro Disorders and Stroke
5/1/10 → 3/31/13
Project: Federal Funding Agencies
-
Low-dose interleukin-2 in patients with mild to moderate Alzheimer’s disease: a randomized clinical trial
Faridar, A., Gamez, N., Li, D., Wang, Y., Boradia, R., Thome, A. D., Zhao, W., Beers, D. R., Thonhoff, J. R., Nakawah, M. O., Roman, G. C., Volpi, J. J., Toledo Atucha , J., George, M., Davis, C. S., Pascual, B., Grundman, M., Masdeu, J. C. & Appel, S. H., Jul 4 2025, In: Alzheimer's Research and Therapy. 17, 1, p. 146 146.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Peripheral monocyte transcriptional signatures of inflammation and oxidative stress in Parkinson's disease
Thome, A. D., Wang, J., Atassi, F., Thonhoff, J. R., Faridar, A., Zhao, W., Beers, D. R., Lai, E. C. & Appel, S. H., Jul 23 2025, In: Frontiers in immunology. 16, p. 1571074Research output: Contribution to journal › Article › peer-review
-
Peripheral monocyte transcriptional signatures of inflammation and oxidative stress in Parkinson’s disease
Thome, A. D., Wang, J., Atassi, F., Thonhoff, J. R., Faridar, A., Zhao, W., Beers, D. R., Lai, E. C. & Appel, S. H., 2025, In: Frontiers in immunology. 16, 1571074.Research output: Contribution to journal › Article › peer-review
Open Access -
A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic lateral sclerosis
Thonhoff, J. R., Beers, D. R., Zhao, W., Faridar, A., Thome, A., Wen, S., Zhang, A., Wang, J. & Appel, S. H., 2024, In: Frontiers in Neurology. 15, p. 1415106 1415106.Research output: Contribution to journal › Article › peer-review
Open Access10 Scopus citations -
A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease
Faridar, A., Eid, A. M., Thome, A. D., Zhao, W., Beers, D. R., Pascual, M. B., Nakawah, M. O., Roman, G. C., Davis, C. S., Grundman, M., Masdeu, J. C. & Appel, S. H., Nov 16 2023, In: Translational Neurodegeneration. 12, 1, p. 54 54.Research output: Contribution to journal › Letter › peer-review
Open Access16 Scopus citations